Skip to main content

Table 1 Patient characteristics

From: The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

  STF Non-STF P Value
(n = 7) (n = 6)
Median Age (range), Years 51 (47–64) 52 (44–69) 1.00
Median Body Mass Index (SEM), kg/m2 25.5 (3.3) 23.8 (2.4) 0.53
WHO-status
Grade 0 6 (85.7 %) 6 (100 %) 0.34
Grade 1 1 (14.3 %) 0 (0.0 %)
Treatment
Adjuvant 5 (71.4 %) 3 (50.0 %) 0.43
Neo-adjuvant 2 (28.6 %) 3 (50.0 %)
T-classification
T1 3 (42.9 %) 2 (33.3 %) 0.94
T2 3 (42.9 %) 3 (50.0 %)
T3 1 (14.3 %) 1 (16.7 %)
N-classification
N0 2 (28.6 %) 2 (33.3 %) 0.85
N+ 5 (71.4 %) 4 (66.7 %)
Stage
II 4 (57.2 %) 5 (83.3 %) 0.31
III 3 (42.9 %) 1 (16.7 %)
ER-status
ER- 1 (14.3 %) 3 (50.0 %) 0.16
ER+ 6 (85.7 %) 3 (50.0 %)
PR-status
PR- 3 (42.9 %) 4 (66.7 %) 0.39
PR+ 4 (57.1 %) 2 (33.3 %)
Grade (BR)
1 1 (14.3 %) 1 (16.7 %) 0.44
2 2 (28.6 %) 4 (66.7 %)
3 3 (42.9 %) 1 (16.7 %)
Unknown 1 (14.3 %) 0 (0.0 %)
Chemotherapy related adjustment
No 3 (42.9 %) 3 (50.0 %) 0.80
Yes 4 (57.1 %) 3 (50.0 %)
  1. STF short-term fasting, SEM standard error of the mean, ER estrogen receptor; PR progesterone receptor, BR Bloom-Richardson